The Beijing Municipal Health Insurance Administration issued “Certain Measures to Support the High-Quality Development of Innovative Medicines in Beijing”. Among them, it was mentioned to promote the implementation of a national innovation pilot project to “reduce the review time limit for drug supplement applications from 200 days to 60 days, and reduce the approval time limit for drug clinical trials from 60 days to 30 days”. Key project management mechanisms have been implemented for innovative pharmaceutical companies, with “one product, one policy”, early intervention, and full guidance in terms of registration and licensing. By the end of 2024, the total number of varieties included in project management will increase to 200.